Minced cartilage implant may outperform standard microfracture for hip damage
NCT ID NCT07657871
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares two surgical techniques for repairing cartilage damage in the hip caused by femoroacetabular impingement (FAI). One method, microfracture, creates tiny bone fractures to stimulate new cartilage growth. The other, minced cartilage implantation, uses the patient's own cartilage tissue, ground up and mixed with platelet-rich plasma, to patch the defect. Researchers will enroll 180 adults aged 18-50 and track their hip function and quality of life over time to see which approach works better.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- minced cartilage implantation (autologous cartilage with platelet-rich plasma)
- What this could lead to
- If it works, this could offer a better surgical option for repairing hip cartilage damage, potentially delaying or preventing the need for hip replacement.
- What could go wrong
- This is a relatively early-stage comparison with 180 participants. The procedure is surgical and carries standard risks like infection or incomplete healing. It may not prove superior to microfracture.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 180 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jul 2026
An estimate. Start dates often move.
- Expected to finish
-
Jun 2031
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 50 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patient, male or female, aged 18-50 years old; * Patient with an acetabular chondral lesion due to FAI, characterised as Beck class 4 or 5, measuring 1-6 cm2; * Patient with Tönnis grade 0-2; * Patient who signed the informed consent form and is willing to comply with the protocol requirements based on the investigator's judgment; * Patient affiliated with a social security scheme; * Patient able to answer questionnaires and to communicate freely in French Exclusion Criteria: * Patient with prior ipsilateral hip surgery; * Patient with borderline or frank hip dysplasia (lateral centre edge angle \<25º); * Patient with hyperlaxity (Beighton score \>7); * Patient with any concomitant disease or disorder which, in the opinion of the investigator, may put the patient at risk or may influence the result of the study; * Patient that is pregnant or breastfeeding; * Patient with protected status under articles L1121-6, LL121-8 and L1122-2 of the French Public Health Code; * Patient who cannot comply with the protocol requirements based on the investigator's judgment
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Femoro-acetabular impingement (FAI) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Clinique De La Sauvegarde
Lyon, 69009, France
-
ICOSS
Strasbourg, 67100, France